10,000 Shares in Sanofi (NASDAQ:SNY) Purchased by Corient IA LLC

Key Points

• Corient IA LLC purchased 10,000 shares of Sanofi (NASDAQ:SNY) during the first quarter, investing approximately $555,000.
• Multiple institutional investors have increased their positions in Sanofi, with substantial boosts, including Mirae Asset Global Investments and Axxcess Wealth Management, reflecting growing confidence in the stock.
• Sanofi received a consensus rating of "Buy" from analysts, with a price target averaging $62.00, despite missing earnings expectations in its most recent quarterly report.

Corient IA LLC bought a new position in Sanofi (NASDAQ:SNY - Free Report) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 10,000 shares of the company's stock, valued at approximately $555,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in SNY. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Sanofi by 124.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock worth $1,344,000 after purchasing an additional 13,358 shares during the last quarter. Axxcess Wealth Management LLC boosted its holdings in Sanofi by 130.5% during the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock worth $568,000 after purchasing an additional 5,794 shares during the last quarter. Ballentine Partners LLC boosted its holdings in Sanofi by 68.7% during the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock worth $1,445,000 after purchasing an additional 10,617 shares during the last quarter. Sowell Financial Services LLC purchased a new position in Sanofi during the first quarter worth about $328,000. Finally, Farther Finance Advisors LLC boosted its holdings in Sanofi by 66.2% during the first quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company's stock worth $338,000 after purchasing an additional 2,476 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on SNY shares. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Finally, Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi has a consensus rating of "Buy" and an average price target of $62.00.

Sanofi Stock Performance

NASDAQ SNY opened at $49.77 on Friday. The company has a 50-day simple moving average of $48.57 and a two-hundred day simple moving average of $51.83. The company has a quick ratio of 0.94, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 12-month low of $44.73 and a 12-month high of $60.12. The firm has a market cap of $122.21 billion, a price-to-earnings ratio of 11.96, a PEG ratio of 1.19 and a beta of 0.48.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion for the quarter, compared to analysts' expectations of $9.91 billion. During the same quarter in the prior year, the firm earned $1.73 EPS. The firm's revenue for the quarter was down 7.0% on a year-over-year basis. On average, equities analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.